Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis

Expert Opinion on Investigational Drugs

Volumn 22, Issue 4, 2013, Pages 499-515

  Chakraborty, Sushmita ^a   Chopra, Puneet ^a   Hak, Anushree ^a   Dastidar, Sunanda Ghosh ^a   Ray, Abhijit ^a  

^a MSD Pharmaceutical Private Limited   (India)

Author keywords

Anti fibrotic agents; Apoptosis; Hepatocyte growth factor; Inflammation; Pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANG 1170; ANTIFIBROTIC AGENT; ANTIOXIDANT; AZATHIOPRINE; BB 3; BEPERMINOGENE PERPLASMID; BOSENTAN; CHRONSEAL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACITENTAN; PENICILLAMINE; PIRFENIDONE; PLACEBO; PREDNISONE; RECOMBINANT HUMAN HEPATOCYTE GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ACUTE LUNG INJURY; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ATHEROSCLEROSIS; BUERGER DISEASE; CARDIOMYOPATHY; CELL PROLIFERATION; CRITICAL LIMB ISCHEMIA; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROSING ALVEOLITIS; HEART INFARCTION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; LEG ULCER; LIVER FAILURE; LIVER FIBROSIS; LUNG ALVEOLUS CELL; LUNG FIBROSIS; LYMPHEDEMA; MESENCHYME CELL; MOLECULAR BIOLOGY; MYOFIBROBLAST; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER; UNSPECIFIED SIDE EFFECT;

ANIMALS; HEPATOCYTE GROWTH FACTOR; HUMANS; PULMONARY FIBROSIS;

EID: 84875125485     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.778972     Document Type: Review

References (123)

1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-54
2. Antoniou KM, Pataka A, Bouros D, Siafakas NM. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2007;20:453-61
3. Powell RJ, Goodney P, Mendelsohn FO, et al. HGF-0205 Trial Investigators. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010;52:1525-30
4. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65
5. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417
6. Rennard SI, Bitterman PB, Crystal RG. Response of the lower respiratory tract to injury. Mechanisms of repair of the parenchymal cells of the alveolar wall. Chest 1983;84:735-9
7. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-16
8. Hogan BL, Yingling JM. Epithelial/mesenchymal interactions and branching morphogenesis of the lung. Curr Opin Genet Dev 1998;8:481-6
9. Bostrom H, Willetts K, Pekny M, et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 1996;85:863-73
10. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-46
11. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63
12. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51
13. Adamson IY, Young L, Bowden DH. Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol 1988;130:377-83
14. Evans MJ, Cabral LJ, Stephens RJ, Freeman G. Transformation of alveolar type 2 cells to type 1 cells following exposure to NO2. Exp Mol Pathol 1975;22(1):142-50
15. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008;294(6):L1119-26
16. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178(8):838-46
17. Kuwano K, Kunitake R, Kawasaki M, et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996;154(2 Pt 1):477-83
18. Plataki M, Koutsopoulos AV, Darivianaki K, et al. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005;127:266-74
19. Hagimoto N, Kuwano K, Nomoto Y, et al. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997;16:91-101
20. Uhal BD. Apoptosis in lung fibrosis and repair. Chest 2002;122(6 Suppl):293S-8S
21. Kuwano K, Kunitake R, Maeyama T, et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2001;280:L316-25
22. Lee CG, Cho SJ, Kang MJ, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 2004;200:377-89
23. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13-19
24. Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17:272-8
25. Golan-Gerstl R, Wallach-Dayan SB, Amir G, Breuer R. Epithelial cell apoptosis by fas ligand-positive myofibroblasts in lung fibrosis. Am J Respir Cell Mol Biol 2007;36:270-5
26. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 2005;19:854-6
27. Crestani B, Marchand-Adam S, Quesnel C, et al. Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc 2012;9(3):158-63
28. Christensen PJ, Bailie MB, Goodman RE, et al. Role of diminished epithelial GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2000;279(3):L487-95
29. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97(1):232-7
30. Sisson TH, Hattori N, Xu Y, et al. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999;10(14):2315-23
31. Chan JCY, Duszczyszyn DA, Castellino FJ, et al. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001;159:1681-8
32. Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res 2012;49(1):35-43
33. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-3
34. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122(Suppl 6):286S-9S
35. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-46
36. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004;113:243-52
37. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-32
38. Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003;278:12384-9
39. Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56
40. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16
41. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66
42. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3(4):350-6
43. Horowitz JC, Ajayi IO, Kulasekaran P, et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol 2012;44(1):158-69
44. Tanaka T, Yoshimi M, Maeyama T, et al. Resistance to Fas-mediated apoptosis in human lung fibroblast. Eur Respir J 2002;20:359-68
45. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999;21:658-65
46. Matsuyama W, Watanabe M, Shirahama Y, et al. Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis. Am J Pathol 2006;168:866-77
47. Jordana M, Schulman J, McSharry C, et al. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988;137:579-84
48. Raghu G, Chen YY, Rusch V, Rabinovitch PS. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am Rev Respir Dis 1988;138:703-8
49. Hauber HP, Blaukovitsch M. Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 2010;9(3):158-72
50. Hunninghake GW, Kalica AR. Workshop summary: approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995;151:915-18
51. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. Chest 1996;110:1058-67
52. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178(9):948-55
53. Fulmer J, Elson N, Von Gal E, et al. Treatment of idiopathic pulmonary fibrosis. Clin Res 1978;26:538A
54. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998;158:220-5
55. Chapela R, Zuniga G, Selman M. D-penicillamine in the therapy of fibrotic lung diseases. Int J Clin Pharmacol Ther Toxicol 1986;24:16
56. Mutsaers SE, Marshall RP, Goldsack NR, et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm pharmacol Ther 1998;11(2-3):221-5
57. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med 2010;4:301-10
58. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in Idiopathic Pulmonary Fibrosis: A phase III clinical trial in Japan. Eur Respir J 2010;35:821-821
59. Azuma A, Taguchi Y, Ogura T, et al. Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143
60. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose n-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-901
61. Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77
62. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003;126:469-75
63. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450-9
64. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3
65. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997;239:639-44
66. Bottaro DP, Rubin JS, Faletto DL, et al. A Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 1991;251:802-4
67. Stamos J, Lazarus RA, Yao XY, et al. Crystal structure of the HGF b-chain in complex with the sema domain of the Met receptor. EMBO J 2004;23:2325-35
68. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003;22(2-3):223-36
69. Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J 2010;277:2230-7
70. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195-202
71. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78
72. Gandino L, Longati P, Medico E, et al. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J Biol Chem 1994;269:1815-20
73. Peschard P, Ishiyama N, Lin T, et al. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J BiolChem 2004;279:29565-71
74. Longati P, Bardelli A, Ponzetto C, et al. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994;9:49-57
75. Vigna E, Naldini L, Tamagnone L, et al. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol (Noisy-le-grand) 1994;40(5):597-604
76. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 1997;16:2634-45
77. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011;3(1 Suppl):S7-S19
78. Maulik G, Madhiwala P, Brooks S, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6:539-53
79. Graziani A, Gramaglia D, dalla Zonca P, et al. Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem 1993;268:9165-8
80. Paumelle R, Tulasne D, Kherrouche Z, et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002;21:2309-19
81. Fixman ED, Fournier TM, Kamikura DM, et al. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem 1996;271:13116-22
82. Xiao GH, Jeffers M, Bellacosa A, et al. Antiapoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-52
83. Garcia-Guzman M, Dolfi F, Zeh K, Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene 1999;18:7775-86
84. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994;9:2019-27
85. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391:285-8
86. Syed ZA, Yin W, Hughes K, et al. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 2011;11:180
87. Zhang YW, Wang LM, Jove R, Vande Woude GF. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 2002;21:217-26
88. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71
89. Rahimi N, Hung W, Tremblay E, et al. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 1998;273:33714-21
90. Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 1998;125:1315-24
91. Yanagita K, Matsumoto K, Sekiguchi K, et al. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem 1997;268:21212-17
92. Phin S, Marchand-Adam S, Fabre A, et al. Imbalance in the prohepatocyte growth factor activation system in bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 2010;42:286-93
93. Marchand-Adam S, Marchal J, Cohen M, et al. Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:1156-61
94. Marchand-Adam S, Fabre A, Mailleux AA, et al. Defect of prohepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:58-66
95. Dohi M, Hasegawa T, Yamamoto K, Marshall BC. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000;162(6):2302-7
96. Watanabe M, Ebina M, Orson FM, et al. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 2005;12(1):58-67
97. Umeda Y, Marui T, Matsuno Y, et al. Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab Invest 2004;84(7):836-44
98. Leuenberger A, Gazdhar A, Herrmann G, et al. Cell-specific expression of human HGF by alveolar type II cells induces remodeling of septal wall tissue in the lung: a morphometric study. J Appl Physiol 2012;113(5):799-807
99. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 1997;156:1937-44
100. Gazdhar A, Temuri A, Knudsen L, et al. Targeted gene transfer of hepatocyte growth factor to alveolar type II epithelial cells reduces lung fibrosis in rats. Hum Gene Ther 2013;24:105-16
101. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41
102. Nakagami H, Morishita R, Yamamoto K, et al. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 2001;37(2 Pt 2):581-6
103. Wang X, Zhou Y, Kim HP, et al. Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells. J Biol Chem 2004;279(7):5237-43
104. Mason RJ, McCormick-Shannon K, Rubin JS, et al. Hepatocyte growth factor is a mitogen for alveolar type II cells in rat lavage fluid. Am J Physiol 1996;271(1 Pt 1):L46-53
105. Bardelli A, Longati P, Albero D, et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-12
106. Kim HJ, Sammak PJ, Ingbar DH. Hepatocyte growth factor stimulates migration of type II alveolar epithelial cells on the provisional matrix proteins fibronectin and fibrinogen. Chest 1999;116:94S-5S
107. Shiratori M, Michalopoulos G, Shinozuka H, et al. Hepatocyte growth factor stimulates DNA synthesis in alveolar epithelial type II cells in vitro. Am J Respir Cell Mol Biol 1995;12(2):171-80
108. Okada M, Sugita K, Inukai T, et al. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-alpha or oxidative stress. Pediatr Res 2004;56(3):336-44
109. Gazdhar A, Fachinger P, van Leer C, et al. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007;292(2):L529-36
110. Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol 1999;277(4 Pt 2):F624-33
111. Togo S, Sugiura H, Nelson A, et al. Hepatic growth factor (HGF) inhibits cigarette smoke extract induced apoptosis in human bronchial epithelial cells. Exp Cell Res 2010;316(20):3501-11
112. Wang R, Alam G, Zagariya A, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 2000;185:253-9
113. Wang R, Zagariya A, Ang E, et al. Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol 1999;277:L1245-50
114. Wang R, Ibarra-Sunga O, Verlinski L, et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000;279:L143-51
115. Day RM, Thiel G, Lum J, et al. Hepatocyte growth factor regulates angiotensin converting enzyme expression. J Biol Chem 2004;279:8792-801
116. Shukla MN, Rose JL, Ray R, et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009;40:643-53
117. Makondo K, Kimura K, Kitamura N, et al. Hepatocyte growth factor activates endothelial nitric oxide synthase by Ca(2+)-and phosphoinositide 3-kinase/Aktdependent phosphorylation in aortic endothelial cells. Biochem J 2003;374:63-9
118. Vyas-Read S, Shaul PW, Yuhanna IS, Willis BC. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007;293:L212-21
119. Moore AE, Greenhough A, Roberts HR, et al. HGF/Met signalling promotes PGE (2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 2009;30:1796-804
120. Lee YH, Suzuki YJ, Griffin AJ, Day RM. Hepatocyte growth factor regulates cyclooxygenase-2 expression via beta-catenin, Akt, and p42/p44 MAPK in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008;294:L778-86
121. Thomas PE, Peters-Golden M, White ES, et al. PGE(2) inhibition of TGF-beta1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol 2007;293:L417-28
122. Mizuno S, Matsumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 2005;19:580-2
123. Nagai A, Chiyotani A, Nakadate T, Konno K. Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J Exp Med 1992;167:231-7